Teva plots Japanese joint venture; Suisse boosts Novartis, bumps Sanofi;

> Teva Pharmaceutical Industries is in talks to set up a development and sales joint venture with Japan's Kowa as part of comprehensive effort to break into the Japanese market. Report

> Credit Suisse upgraded Novartis to "outperform" because the stock has "defensive characteristics;" meanwhile, the bank downgraded Sanofi-Aventis to "underperform," saying that it's under pressure from the possible spread of Plavix generics in Europe. Report

> Sanofi-Aventis got the FDA nod to market its Nasacort nasal spray for use in children 2-5 years. Sanofi release

> UK-based Archimedes Pharma launched its Zibor heparin product in its home market for post-operative clotting prevention. Report

> Anika Therapeutics inked an exclusive distribution agreement with a Johnson & Johnson subsidiary, under which DePuy Mitek will market Orthovisc-branded hyaluronic acid products in Latin America. Report

> Sanofi-Aventis has recalled remaining batches of its contaminated blood thinner Lovenox, a heparin product, which were distributed before May 2008. Report

> Drug delivery specialist Tris Pharma wrapped up an expansion of its New Jersey research and manufacturing building, with the addition of 15,000 square feet of space to its FDA-compliant facility. Tris release

> Canada's Angiotech Pharmaceuticals is restructuring its operations as a badly needed investment of up to $300 million appears to be in doubt now. Report

> Encorium Group, a multinational CRO, says that it is delaying a planned acquisition and will cut 18 percent of its U.S. staff. Report

> The UK's Allergy Therapeutics says that a late-stage trial of its ragweed vaccine proved positive, with a statistically significant improvement in comparison to a placebo. Report

> One of the biggest moves in biopharma this week will turn on the FDA's decision on prasugrel, a blood-clot drug advanced by Eli Lily and Daiichi Sankyo. Report

> The UK's Allergy Therapeutics says that a late-stage trial of its ragweed vaccine proved positive, with a statistically significant improvement in comparison to a placebo. Report

> OpGen was a tiny Madison, WI-based company with only five employees. Now with $220k in state and local loans and $23.6 million in financing, the Gaithersburg-based company plans to add 100 more to its 55 employees as it ramps up sales efforts. Report

> Genzyme has opened the doors to a new, 180,000-square-foot research facility in Framingham, MA that will eventually house some 350 investigators and other staffers. Report

> Investigators at the University of Wisconsin have made a key breakthrough in the use of adult stem cells to treat ALS. Report

And Finally... Alzheimer's patients who take both a cholinesterase inhibitor and memantine showed a significantly smaller rate of decline than those on no medication or a sholinesterase inhibitor alone. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.